Elanco Animal Health (ELAN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Elanco Animal Health.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 26.40 $ — 97% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.3% failed
- More than 10% revenue growth is expected for the coming year 5.3% failed
- Share count grows by less than 3% a year 0.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 12.2% failed
- Gross margin at 40% or higher and without meaningful erosion 43.5% passed
- Goodwill from acquisitions does not grow faster than revenue 35.8% passed
- Net debt below twice EBITDA 5.1 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,497 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.1% failed
- Insiders hold at least 10% or are net buyers 1.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 13.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 15
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.07 | 1.02 – 1.10 | 5,054 | 13.4% | 14 |
| 12/31/2027 | 1.20 | 1.14 – 1.24 | 5,321 | 12.2% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.27 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.02 | – | 1,020 | -1.40 | -0.80 | 177 | 124 |
| 2025: Q1 | 0.13 | 108.10 | 1,193 | -1.00 | 5.60 | -4 | -69 |
| 2025: Q2 | 0.02 | – | 1,241 | 4.80 | 0.90 | 237 | 180 |
| 2025: Q3 | -0.07 | -109.40 | 1,137 | 10.40 | -3.00 | 219 | 127 |
| 2025: Q4 | -0.56 | – | 1,144 | 12.20 | -24.10 | 108 | 46 |
| 2026: Q1 | 0.11 | -16.10 | 1,371 | 14.90 | 4.20 | 13 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,914 | 283 | -48 | -0.13 | 156 | 7,028 | 8,100 |
| 2017 | 2,889 | 142 | -311 | -0.87 | 174 | 7,791 | 8,940 |
| 2018 | 3,067 | 314 | 87 | 0.28 | 487 | 5,198 | 8,957 |
| 2019 | 3,071 | 370 | 68 | 0.18 | 224 | 5,547 | 8,986 |
| 2020 | 3,273 | -77 | -560 | -1.27 | -41 | 8,476 | 17,693 |
| 2021 | 4,764 | 304 | -483 | -0.99 | 483 | 7,508 | 16,478 |
| 2022 | 4,411 | 384 | -78 | -0.16 | 452 | 7,289 | 15,491 |
| 2023 | 4,417 | 326 | -1,231 | -2.50 | 271 | 6,223 | 14,362 |
| 2024 | 4,439 | 251 | 338 | 0.68 | 541 | 6,096 | 12,614 |
| 2025 | 4,715 | 252 | -232 | -0.47 | 560 | 6,547 | 13,358 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Elanco Animal Health Incorporated ist ein Tiergesundheitsunternehmen, das weltweit Produkte für Heim- und Nutztiere innoviert, entwickelt, fertigt und vermarktet. Das Unternehmen bietet Heimtiergesundheitsprodukte wie Parasitizide, Impfstoffe und Therapeutika an, die Tiere vor Flöhen, Zecken und inneren Parasiten schützen.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 9,400 |
| Headquarters | Indianapolis, IN |
| Address | 450 Elanco Circle, 46221 Indianapolis, United States |
| Phone | 877 352 6261 |
| Website | elanco.com |
| IPO Date | 20. Sep 2018 |
| ISIN | US28414H1032 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey N. Simmons | President, CEO & Director | 1967 |
| Robert M. VanHimbergen | Executive VP & CFO | 1976 |
| Ramiro Martin Cabral | Executive VP & President of Elanco International | 1972 |
| Ellen de Brabander Ph.D. | Executive Vice President of Research, Development & Regulatory Affairs | 1963 |
| Timothy J. Bettington | Executive Vice President of Center of Strategic Growth | 1974 |
| James M. Meer | Senior VP & Chief Accounting Officer | 1970 |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration | 1967 |
| Tiffany Ann Kanaga | VP of Investor Relations & ESG | – |
| Shiv O'Neill | Executive Vice President, General Counsel & Corporate Secretary | 1975 |
| Larbi Van Lier | Senior Vice President of Asia | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7. Jul 2026 | VanHimbergen Robert M | EVP and CFO | Other | 15,336 | 24.64 | 377,879 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.